1.De Angelis, D, et al. An evidence synthesis approach to estimating Hepatitis C prevalence in England and Wales. Statistical Methods in Medical Research 2009; 18: 361–379.
2.EMCDDA. Statistical Bulletin 2010, Table INF-2. Lisbon: EMCCDA, 2010.
3.Sweeting, MJ, et al. Hepatitis C infection among injecting drug users in England and Wales (1992–2006): there and back again? American Journal of Epidemiology 2009; 170: 352–360.
4.Craine, N, et al. Incidence of hepatitis C in drug injectors: the role of homelessness, opiate substitution treatment, equipment sharing, and community size. Epidemiology and Infection 2009; 137: 1255–1265.
5.Hickman, M, et al. Hepatitis C virus (HCV) prevalence, and injecting risk behaviour in multiple sites in England in 2004. Journal of Viral Hepatitis 2007; 14: 645–652.
6.Judd, A, et al. Incidence of hepatitis C virus and HIV among new injecting drug users in London: prospective cohort study. British Medical Journal 2005; 330: 24–25.
7.Hope, VD, et al. Measuring the incidence, prevalence and genetic relatedness of hepatitis C infections among a community recruited sample of injecting drug users, using dried blood spots. Journal of Viral Hepatitis. Published online: 27 April 2010. doi: 10.1111/j.1365-2893.2010.01297.x.
8.Martin, N, et al. Can antiviral therapy for hepatitis C reduce the prevalence of HCV among injecting drug user populations? A modelling analysis of its prevention utility. Journal of Hepatology. Published online: 22 October 2010. doi:10.1016/j.jhep.2010.08.029.
9.Vickerman, P, Hickman, M, Judd, A. Modelling the impact on Hepatitis C transmission of reducing syringe sharing: London case study. International Journal of Epidemiology 2007; 36: 396–405.
10.Hickman, M, et al. Injecting drug use in Brighton, Liverpool, and London: best estimates of prevalence and coverage of public health indicators. Journal of Epidemiology and Community Health 2004; 58: 766–771.
11.Hope, VD, et al. Prevalence of hepatitis C among injection drug users in England and Wales: is harm reduction working? American Journal of Public Health 2001; 91: 38–42.
13.Health Protection Agency.Shooting up: infections among injecting drug users in the United Kingdom 2008. London: Health Protection Agency, 2009.
14.Ghangurde, PD, Singh, MP. Synthetic estimation in periodic household surveys. Survey Methodology, Statistics Canada 1977; 3: 152–181.
15.Rhodes, WR. Synthetic estimation applied to the prevalence of drug use. Journal of Drug Issues 1993; 23: 297–321.
16.Bajekal, M et al. Synthetic estimation of healthy lifestyles indicators: Stage 1 report. London: National Centre for Social Research, 2004.
17.Rao, JNK. Small Area Estimation. New York: Wiley, 2003.
18.Best, N, Richardson, S, Thomson, A. A comparison of Bayesian spatial models for disease mapping. Statistical Methods in Medical Research 2005; 14: 35–59.
19.Judd, A, et al. Evaluation of a modified commercial assay in detecting antibody to hepatitis C virus in oral fluids and dried blood spots. Journal of Medical Virology 2003; 71: 49–55.
21.Office for National Statistics. Mid-year population estimates: quinary age groups and sex for local authorities in England and Wales; estimated resident population based on the 2001 Census. London: Office for National Statistics, 2008.
23.Besag, J, York, J, Mollie, A. A Bayesian image restoration, with two applications in spatial statistics. Annals of the Institute of Statistical Mathematics 1991; 43: 1–59.
24.Gelman, A. Prior distributions for variance parameters in hierarchical models. Bayesian Analysis 2006; 1: 515–533.
25.Spiegelhalter, D, et al. WinBUGS Version 1.4 User Manual. Cambridge: MRC Biostatistics Unit, 2003.
26.Brooks, SP and Gelman, A. General methods for monitoring convergence of iterative simulations. Journal of Computational and Graphical Statistics 1998; 7: 434–455.
27.Spiegelhalter, D, Best, NG, Carlin, BP. Bayesian measures of model complexity and fit. Journal of the Royal Statistical Society, Series B: Statistical Methodology 2002; 64: 583–639.
28.Van Houwelingen, JC, le Cessie, S. Predictive value of statistical models. Statistics in Medicine 1990; 9: 1303–1325.
29.Stern, HS, Cressie, N. Posterior predictive model checks for disease mapping models. Statistics in Medicine 2000; 19: 2377–2397.
30.May, M, et al. Development and validation of a prognostic model for survival time data: application to prognosis of HIV positive patients treated with antiretroviral therapy. Statistics in Medicine 2004; 23: 2375–2398.
31.Kelsall, J, Wakefield, J. Discussion of ‘Bayesian models for spatially correlated disease and exposure data’. In: Bernado, J, Berger, J, Dawid, A, eds. Bayesian Statistics 6. Oxford: Oxford University Press, 1999.
32.Marshall, EC, Spiegelhalter, DJ. Approximate cross-validatory predictive checks in disease mapping models. Statistics in Medicine 2003; 22: 1649–1660.
33.Heckathorn, D. Respondent-driven sampling: a new approach to the study of hidden populations. Social Problems 1997; 44: 174–199.
34.Malekinejad, M, et al. Using respondent-driven sampling methodology for HIV biological and behavioral surveillance in international settings: a systematic review. AIDS Behaviour 2008; 12: S105–S130.
35.Hickman, M, et al. Assessing IDU prevalence and health consequences (HCV, overdose and drug-related mortality) in a primary care trust: implications for public health action. Journal of Public Health (Oxford) 2009; 31: 374–382.
36.Goel, S, Salganik, MJ. Assessing respondent-driven sampling. Proceedings of the National Academy of Sciences USA 2010; 107: 6743–6747.